iomazenil (123i)
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00611572)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)c1ncn2c1CN(C)C(=O)c1c(I)cccc1-2- Mol. weight
- 411.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Imaging
- 123-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2110679 ↗
- ChEMBLCHEMBL2105020 ↗
Also known as
- (123i)iomazenil
- ethyl 7-iodo-5,6-dihydro-5-methyl-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
- hyl 5,6-dihydro-7-iodo-(sup 123 sup)i-5-methyl-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
- iomazenil
- iomazenil
- iomazenil
- iomazenil
- iomazenil
- iomazenil
- iomazenil (123i)
- iomazenil (123i)
- iomazenil (123i)
- iomazenil i-123
- ro 16-0154
- ro-16-0154
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01590277 | Phase 2 | Jul 1, 2012 | Department of Veteran Affairs |
| NCT00982982 | Phase 1 | Feb 1, 2009 | Yale University |
| NCT00611572 | Phase 1 | Jan 1, 2007 | Brain & Behavior Research Foundation, Yale University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yale University | Academic/Hospital | 2 | 2 | 1 | 2007 |
| Brain & Behavior Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1